GaBI Generics and Biosimilars Initiative
GaBI Generics and Biosimilars Initiative
3 FOLLOWERS
Generics and Biosimilars Initiative (GaBI) was founded in 2008 by Pro Pharma Communications International. Its mission is to foster the worldwide efficient use of high-quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable, and sustainable health care.
EMA recommends approval of first omalizumab biosimilar Omlyclo
GaBI Generics and Biosimilars Initiative
by
1d ago
..read more
Visit website
Unveiling key clinical findings for denosumab biosimilar candidates
GaBI Generics and Biosimilars Initiative
by
1d ago
..read more
Visit website
Three more biosimilar approvals in Canada in 2023
GaBI Generics and Biosimilars Initiative
by
1d ago
..read more
Visit website
Addressing the persistent gap in Medicare access to Humira biosimilars
GaBI Generics and Biosimilars Initiative
by
3w ago
..read more
Visit website
Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
GaBI Generics and Biosimilars Initiative
by
3w ago
..read more
Visit website
EMA recommends approval of first denosumab biosimilar Jubbonti and Wyost
GaBI Generics and Biosimilars Initiative
by
1M ago
..read more
Visit website
Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
GaBI Generics and Biosimilars Initiative
by
1M ago
..read more
Visit website
Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
GaBI Generics and Biosimilars Initiative
by
1M ago
..read more
Visit website
Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
GaBI Generics and Biosimilars Initiative
by
1M ago
..read more
Visit website
First denosumab biosimilars approved in Canada and the US
GaBI Generics and Biosimilars Initiative
by
1M ago
..read more
Visit website

Follow GaBI Generics and Biosimilars Initiative on FeedSpot

Continue with Google
Continue with Apple
OR